IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
Yifan ZhangYuanpeng LiaoMayao LuoYuedian YeZhuofan XuWenli HouRuiyu LiuQiliang ZhaiShidong LvQiang WeiPublished in: The Prostate (2023)
Taken together, our findings suggest that the combination of AR degrader and enzalutamide potentially represents a new therapeutic strategy for CRPC.
Keyphrases